Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

Litchlab Launches Advanced Precision PEGylation Platform to Empower Long-Acting Biologics and Nucleic Acid Drug Delivery

As the pharmaceutical industry advances into a new era of precision therapeutics, molecular modification technologies are emerging as critical tools to enhance drug pharmacokinetics, safety, and delivery efficiency. Litchlab is proud to announce the full launc...

Litchlab Expands Precision Delivery Frontiers with Advanced Receptor-Drug Conjugate (RDC) Platform

In the rapidly evolving field of targeted therapeutics, Receptor-Drug Conjugates (RDCs) are emerging as a promising next-generation alternative to conventional Antibody-Drug Conjugates (ADCs), offering improved tissue penetration, reduced immunogenicity, and e...

Litchlab Advances ADC Drug Delivery Technology with Comprehensive Platform for Linker Design, Payload Encapsulation, and CMC Excellence

As Antibody-Drug Conjugates (ADCs) rapidly emerge as one of the most transformative innovations in oncology and targeted therapy, Litchlab, a global contract development and manufacturing (CDMO) company specializing in drug delivery platforms, today announced ...

Litchlab Unveils Comprehensive Multi-Molecule Drug Delivery Platform to Accelerate Translational Innovation in Complex TherapiesLitchlab Unveils Comprehensive Multi-Molecule Drug Delivery Platform to Accelerate Translational Innovation in Complex Therapies

As the pharmaceutical industry moves toward increasingly complex therapeutic modalities—ranging from mRNA and gene editing to protein biologics and targeted small molecules—the demand for multi-compatible, customizable, and clinically translatable drug deliver...

Litchlab Strengthens Liposomal Drug Delivery Capabilities with End-to-End Global CDMO Services

As the global pharmaceutical industry accelerates toward advanced delivery technologies, liposomes have emerged as a cornerstone in modern drug delivery platforms, driven by the rising complexity of drug pipelines, regulatory scrutiny, and demand for targeted ...

Litchlab Unveils Next-Generation Vaccine Delivery Platforms, Bridging Innovation and Global Clinical Needs

As the global demand for efficient, stable, and scalable vaccine delivery systems continues to escalate, Litchlab is accelerating its strategic expansion into next-generation vaccine delivery technologies. Leveraging its deep expertise in nanocarriers, formula...

上一页 1 2 3 4 5 下一页